Ten-year outcomes of high-dose, intensity-modulated radiotherapy for localized prostate cancer

Cancer

Volumn 117, Issue 7, 2011, Pages 1429-1437

  Alicikus, Zumre A ^a   Yamada, Yoshiya ^a   Zhang, Zhigang ^a   Pei, Xin ^a   Hunt, Margie ^a   Kollmeier, Marisa ^a   Cox, Brett ^a   Zelefsky, Michael J ^a,b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b Department of Radiation Oncology ^*  (United States)

Author keywords

high dose; intensity modulated radiotherapy; prostate cancer; prostate specific antigen

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; BIOCHEMISTRY; CANCER MORTALITY; CANCER RELAPSE; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DISTANT METASTASIS; ERECTILE DYSFUNCTION; FOLLOW UP; GASTROINTESTINAL DISEASE; HUMAN; INTENSITY MODULATED RADIATION THERAPY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; RADIATION DOSE; RADIATION INJURY; RISK ASSESSMENT; TREATMENT OUTCOME; UROGENITAL TRACT DISEASE;

AGED; AGED, 80 AND OVER; DISEASE-FREE SURVIVAL; ERECTILE DYSFUNCTION; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; RADIOTHERAPY, INTENSITY-MODULATED; TREATMENT OUTCOME;

EID: 79952860759     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.25467     Document Type: Article

References (34)

1. Pollack A, Hanlon AL, Horwitz EM, et al. Prostate cancer radiotherapy dose response: an update of the Fox Chase experience. J Urol. 2004; 171: 1132-1136. (Pubitemid 38327542)
2. Pollack A, Zagars GK, Starkschall G, et al. Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys. 2002; 53: 1097-1105. (Pubitemid 34787842)
3. Peeters ST, Heemsbergen WD, Koper PC, et al. Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. J Clin Oncol. 2006; 24: 1990-1996. (Pubitemid 46622106)
4. Zelefsky MJ, Fuks Z, Hunt M, et al. High-dose intensity modulated radiation therapy for prostate cancer: early toxicity and biochemical outcome in 772 patients. Int J Radiat Oncol Biol Phys. 2002; 53: 1111-1116. (Pubitemid 34787844)
5. Zelefsky MJ, Chan H, Hunt M, Yamada Y, Shippy AM, Amols H., Long-term outcome of high dose intensity modulated radiation therapy for patients with clinically localized prostate cancer. J Urol. 2006; 176 (4 pt 1): 1415-1419. (Pubitemid 44307191)
6. Cahlon O, Zelefsky MJ, Shippy A, et al. Ultra-high dose (86.4 Gy) IMRT for localized prostate cancer: toxicity and biochemical outcomes. Int J Radiat Oncol Biol Phys. 2008; 71: 330-337.
7. Zietman AL, DeSilvio ML, Slater JD, et al. Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial. JAMA. 2005; 294: 1233-1239. (Pubitemid 41352111)
8. Dearnaley DP, Sydes MR, Graham JD, et al. Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial. Lancet Oncol. 2007; 8: 475-487. (Pubitemid 46805903)
9. Zelefsky MJ, Hunt MA, Fuks Z, et al. Long-term distant metastases-free survival and cause-specific survival outcomes after high dose conformal radiotherapy for clinically localized prostate cancer. Int J Radiat Oncol Biol Phys. 2006; 66 (suppl 1): S9-S9.
10. Peeters ST, Heemsbergen WD, van Putten WL, et al. Acute and late complications after radiotherapy for prostate cancer: results of a multicenter randomized trial comparing 68 Gy to 78 Gy. Int J Radiat Oncol Biol Phys. 2005; 61: 1019-1034. (Pubitemid 40340897)
11. Storey MR, Pollack A, Zagars G, Smith L, Antolak J, Rosen I., Complications from radiotherapy dose escalation in prostate cancer: preliminary results of a randomized trial. Int J Radiat Oncol Biol Phys. 2000; 48: 635-642.
12. Zelefsky MJ, Fuks Z, Hunt M, et al. High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer. J Urol. 2001; 166: 876-881. (Pubitemid 32750970)
13. Zelefsky MJ, Fuks Z, Happersett L, et al. Clinical experience with intensity modulated radiation therapy (IMRT) in prostate cancer. Radiother Oncol. 2000; 55: 241-249. (Pubitemid 30408370)
14. Zelefsky MJ, Cowen D, Fuks Z, et al. Long term tolerance of high dose 3-dimensional conformal radiotherapy in patients with localized prostate carcinoma. Cancer. 1999; 85: 2460-2468. (Pubitemid 29244857)
15. Burman CM, Chui CS, Kutcher GJ, et al. Planning, delivery, and quality assurance of intensity-modulated radiotherapy using dynamic multileaf collimator: a strategy for large-scale implementation for the treatment of carcinoma of the prostate. Int J Radiat Oncol Biol Phys. 1997: 39: 863-873.
16. Zelefsky MJ, Happersett L, Leibel SA, et al. The effect of treatment positioning on normal tissue dose in patients with prostate cancer treated with 3-dimensional conformal radiotherapy. Int J Radiat Oncol Biol Phys. 1997; 37: 13-19. (Pubitemid 27090130)
17. Chui C-S, Spirou SV., Inverse planning algorithms for external beam radiation therapy. Med Dosim. 2001; 26: 189-197. (Pubitemid 32496154)
18. Mohan R, Wang X, Jackson A, et al. The potential and limitations of the inverse radiotherapy technique. Radiother Oncol. 1994; 32: 232-248. (Pubitemid 24324203)
19. Thames H, Kuban D, Levy L, et al. Comparison of alternative biochemical failure definitions based on clinical outcome in 4839 prostate cancer patients treated by external beam radiotherapy between 1986 and 1995. Int J Radiat Oncol Biol Phys. 2003; 57: 929-943. (Pubitemid 37324110)
20. Michalski JM, Winter K, Purdy JA, et al. Preliminary evaluation of low-grade toxicity with conformal radiation therapy for prostate cancer on RTOG 9406 dose levels I and II. Int J Radiat Oncol Biol Phys. 2003; 56: 192-198. (Pubitemid 36403691)
21. Kupelian PA, Ciezki J, Reddy CA, Klein EA, Mahadevan A., Effect of increasing radiation doses on local and distant failures in patients with localized prostate cancer. Int J Radiat Oncol Biol Phys. 2008; 71: 16-22. (Pubitemid 351491401)
22. Jacob R, Hanlon AL, Horwitz EM, et al. The relationship of increasing radiotherapy dose to reduced distant metastases and mortality in men with prostate cancer. Cancer. 2004; 100: 538-543. (Pubitemid 38124771)
23. Morgan PB, Hanlon AL, Horwitz EM, Buyyounouski MK, Uzzo RG, Pollack A., Timing of biochemical failure and distant metastatic disease for low-, intermediate-, and high-risk prostate cancer after radiotherapy. Cancer. 2007; 110: 68-80. (Pubitemid 46986420)
24. Zelefsky MJ, Yamada Y, Fuks Z, et al. Long-term results of conformal radiotherapy for prostate cancer: impact of dose escalation on biochemical tumor control and distant metastases-free survival outcomes. Int J Radiat Oncol Biol Phys. 2008; 71: 1028-1033.
25. Morgan PB, Hanlon AL, Horwitz EM, et al. Radiation dose and late failures in prostate cancer. Int J Radiat Oncol Biol Phys. 2007; 67: 1074-1081.
26. Kuban DA, Tucker SL, Dong L, et al. Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys. 2008; 70: 67-74. (Pubitemid 350251041)
27. Al-Mamgani A, van Putten WL, Heemsbergen WD, et al. Update of Dutch multicenter dose-escalation trial of radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys. 2008; 72: 980-988.
28. Zelefsky MJ, Levin EJ, Hunt M, et al. Incidence of late rectal and urinary toxicities after 3-dimensional conformal radiotherapy and intensity-modulated radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys. 2008; 70: 1124-1129. (Pubitemid 351296130)
29. Hanks GE, Pajak TF, Porter A, et al. Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92-02. J Clin Oncol. 2003; 21: 3972-3978. (Pubitemid 46606211)
30. Valicenti RK, Winter K, Cox JD, et al. RTOG 94-06: is the addition of neoadjuvant hormonal therapy to dose-escalated 3D conformal radiation therapy for prostate cancer associated with treatment toxicity? Int J Radiat Oncol Biol Phys. 2003; 57: 614-620. (Pubitemid 37194286)
31. Heemsbergen WD, Peeters STH, Koper PCM, Hoogeman MS, Lebesque JV., Acute and late gastrointestinal toxicity after radiotherapy in prostate cancer patients: consequential late damage. Int J Radiat Oncol Biol Phys. 2006; 66: 3-10. (Pubitemid 44175664)
32. Sethi A, Mohideen N, Leybovich L, Mulhall J., Role of IMRT in reducing penile doses in dose escalation for prostate cancer. Int J Radiat Oncol Biol Phys. 2003; 55: 970-978. (Pubitemid 36286999)
33. Van der Wielen GJ, van Putten WL, Incrocci L., Sexual function after 3-dimensional conformal radiotherapy for prostate cancer: results from a dose-escalation trial. Int J Radiat Oncol Biol Phys. 2007; 68: 479-484. (Pubitemid 46694167)
34. Chen CT, Valicenti RK, Lu J, et al. Does hormonal therapy influence sexual function in men receiving 3D conformal radiation therapy for prostate cancer? Int J Radiat Oncol Biol Phys. 2001; 50: 591-595. (Pubitemid 32515318)